What changed in this filing

/stocks — the workspaceLOADING

Item 5. Market for Registrant’s Common Equity

2024-07-01 compared with 2023-06-29 · 28 added, 27 removed, 31 unchanged (64% of the section changed)

6 unchanged sentences

management or others may have a substantial adverse impact on any such market.

had 93 stockholders of record as of June 29, 2023 and an indeterminate number of stockholders who hold shares in “street name”.

had 102 stockholders of record as of July 1, 2024 and an indeterminate number of stockholders who hold shares in “street name”.

are no present material restrictions that limit our ability to pay dividends on our common or preferred stock.

10 unchanged sentences

Sales of Unregistered Securities

October 29, 2021, we issued a private placement memorandum offering to raise up to $500,000 through the issuance of restricted shares

of our common stock (par value $0.001) to qualified investors.

From November 5, 2021 to March 28, 2022, we received subscription agreements

from investors, for 100,000 common shares at a purchase price of $5 per share, including 500,000 warrants exercisable at $5 per share,

vested immediately upon issuance, with a five year expiration.

Proceeds to us totaled $500,000.

February 5, 2022, the Company issued 649,754 warrants to Radiant Life, LLC, 653,150 warrants to the Chairman of the Board of Directors

and a stockholder and 488,583 warrants to Mr.

Dickman in conjunction with various extensions of maturity dates during the period

(see Note 8).

The exercise price of these warrants was $0.05.

The value of the warrants on the date of grant, as calculated by the Black-Scholes-Merton

valuation model, was $1,840,149.

The inputs used in this calculation included a fair value of $1.049 per share, a risk-free rate of 1.76%,

volatility of 131.78% and a dividend rate of 0%.

January 5, 2022, the Company issued 200,000 warrants to Radiant Life, LLC in conjunction with monies borrowed (see Note 8).

price of these warrants was $0.05.

The value of the warrants

on the date of grant, as calculated by the Black-Scholes-Merton valuation model, was $205,393.

The inputs used in this calculation included

a fair value of $1.049 per share, a risk-free rate of 1.43%, volatility of 131.78% and a dividend rate of 0%.

the year ended March 31, 2023 the Company issued 264,600 warrants to the Chairman of the Board of Directors and 120,000 warrants to Radiant

Life, LLC in conjunction with monies borrowed during the period (see Note 8).

The exercise price of these

warrants was $1.05.

The value of the warrants on the date of grant, as calculated by the Black-Scholes-Merton valuation model was $365,502.

The inputs used in this calculation included a fair value of the underlying common stock of $1.049 per share, a risk-free between 3.62%

and 4.31%, volatility between 142.23% and 148.56% and a dividend rate of 0%.

The exercise price of these warrants was $1.05.

of the warrants on the date of grant, as calculated by the Black-Scholes-Merton valuation model was $365,502.

The inputs used in this

calculation included a fair value of the underlying common stock of $1.049 per share, a risk-free between 3.62% and 4.31%, volatility

between 142.23% and 148.56% and a dividend rate of 0%.

the year ended March 31, 2023, the Company issued 339,749 warrants to Mr.

7 unchanged sentences

common stock of $1.049 per share, a risk-free between 3.49% and 3.95%, volatility between 142.92% and 145.49% and a dividend rate of

August 15, 2023, we issued a private placement memorandum offering to raise up to $1,500,000 through the issuance of restricted shares

of our common stock (par value $0.001) to qualified investors.

From September 20, 2023 to October 4, 2023, we received subscription agreements

from investors, for 850,000 common shares at a purchase price of $1 per share, including 1,700,000 warrants exercisable at $0.35 per

share, vested immediately upon issuance, with a five year expiration.

Proceeds to us totaled $850,000.

the year ended March 31, 2024 the Company issued 281,900 warrants to the Chairman of the Board of Directors and 80,000 warrants to Radiant

Life, LLC in conjunction with monies borrowed during the period (see Note 8 to the financial statements included in this report).

The exercise price of these warrants was $1.05.

of the warrants on the date of grant, as calculated by the Black-Scholes-Merton valuation model was $316,756.

The inputs used in this

calculation included a fair value of the underlying common stock of $1.049 per share, a risk-free between 3.36% and 4.29%, volatility

between 86.52% and 89.11% and a dividend rate of 0%.

the year ended March 31, 2024, the Company issued 1,106,000 warrants to Mr.

Dickman, 772,275 warrants to the Chairman of the Board of

Directors, and 699,754 warrants to Radiant Life, LLC in conjunction with an extension of the maturity dates during the period (see Note 8 to the financial statements included in this report) per the terms outlined above.

The exercise price of these warrants was between $0.41 and $1.05.

The value of the warrants on the date

of grant, as calculated by the Black-Scholes-Merton valuation model was $964,277.

The inputs used in this calculation included a fair

value of the underlying common stock between $0.409 and $1.049 per share, a risk-free between 3.80% and 4.01%, volatility between 84.00%

and 89.07% and a dividend rate of 0%.

of Equity Securities by Us and Affiliated Purchasers

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 5. Market for Registrant’s Common Equity